메뉴 건너뛰기




Volumn 75, Issue 5, 2015, Pages 503-514

Abacavir/dolutegravir/lamivudine single-tablet regimen: A review of its use in HIV-1 infection

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DOLUTEGRAVIR; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TABLET;

EID: 84937512262     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0361-6     Document Type: Article
Times cited : (43)

References (55)
  • 1
    • 84940008999 scopus 로고    scopus 로고
    • US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents
    • Accessed 9 Feb 2015
    • US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014. http://aidsinfo.nih.gov/guidelines. Accessed 9 Feb 2015.
    • (2014) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
  • 2
    • 84890494817 scopus 로고    scopus 로고
    • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013)
    • Williams DI, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013). HIV Med. 2014;15(Suppl 1):1-85.
    • (2014) HIV Med. , vol.15 , pp. 1-85
    • Williams, D.I.1    Churchill, D.2    Anderson, J.3
  • 3
    • 84904568743 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel
    • 25038359
    • Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410-25.
    • (2014) JAMA. , vol.312 , Issue.4 , pp. 410-425
    • Günthard, H.F.1    Aberg, J.A.2    Eron, J.J.3
  • 5
    • 84861689822 scopus 로고    scopus 로고
    • Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel
    • W-284-94
    • Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med. 2012;156(11):817-33, W-284-94.
    • (2012) Ann Intern Med , vol.156 , Issue.11 , pp. 817-33
    • Thompson, M.A.1    Mugavero, M.J.2    Amico, K.R.3
  • 6
    • 84880611713 scopus 로고    scopus 로고
    • Spillover adherence effects of fixed-dose combination HIV therapy
    • 3295624 22399848
    • Kauf TL, Davis KL, Earnshaw SR, et al. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012;6:155-64.
    • (2012) Patient Prefer Adherence. , vol.6 , pp. 155-164
    • Kauf, T.L.1    Davis, K.L.2    Earnshaw, S.R.3
  • 7
    • 84864670297 scopus 로고    scopus 로고
    • Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment
    • 22833060
    • Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14(3):168-78.
    • (2012) AIDS Rev. , vol.14 , Issue.3 , pp. 168-178
    • Llibre, J.M.1    Clotet, B.2
  • 8
    • 84977119451 scopus 로고    scopus 로고
    • Single-tablet regimens in HIV therapy
    • 4108118 25134808
    • Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis Ther. 2014;3(1):1-17.
    • (2014) Infect Dis Ther. , vol.3 , Issue.1 , pp. 1-17
    • Astuti, N.1    Maggiolo, F.2
  • 12
    • 84904740227 scopus 로고    scopus 로고
    • Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults
    • 1:CAS:528:DC%2BC2cXhtFCqsbfN 25005775
    • McCormack PL. Dolutegravir: a review of its use in the management of HIV-1 infection in adolescents and adults. Drugs. 2014;74(11):1241-52.
    • (2014) Drugs. , vol.74 , Issue.11 , pp. 1241-1252
    • McCormack, P.L.1
  • 13
    • 80052847538 scopus 로고    scopus 로고
    • Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572)
    • 3187526 1:CAS:528:DC%2BC3MXhs1ansbvI 21719464
    • Hare S, Smith SJ, Métifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011;80(4):565-72.
    • (2011) Mol Pharmacol. , vol.80 , Issue.4 , pp. 565-572
    • Hare, S.1    Smith, S.J.2    Métifiot, M.3
  • 14
    • 78751697293 scopus 로고    scopus 로고
    • In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor
    • 3028777 1:CAS:528:DC%2BC3MXisVyjt7g%3D 21115794
    • Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55(2):813-21.
    • (2011) Antimicrob Agents Chemother. , vol.55 , Issue.2 , pp. 813-821
    • Kobayashi, M.1    Yoshinaga, T.2    Seki, T.3
  • 15
    • 12444279985 scopus 로고    scopus 로고
    • Abacavir plus lamivudine
    • 1:CAS:528:DC%2BD2MXhsFersrw%3D 15631548
    • Dando T, Scott L. Abacavir plus lamivudine. Drugs. 2005;65(2):285-302.
    • (2005) Drugs. , vol.65 , Issue.2 , pp. 285-302
    • Dando, T.1    Scott, L.2
  • 16
    • 84905984152 scopus 로고    scopus 로고
    • Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes
    • 1:CAS:528:DC%2BC2MXis12qsbo%3D 24860155
    • Pollicita M, Surdo M, Di Santo F, et al. Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes. J Antimicrob Chemother. 2014;69(9):2412-9.
    • (2014) J Antimicrob Chemother. , vol.69 , Issue.9 , pp. 2412-2419
    • Pollicita, M.1    Surdo, M.2    Di Santo, F.3
  • 19
    • 84887052771 scopus 로고    scopus 로고
    • Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection [plus supplementary appendix]
    • 1:CAS:528:DC%2BC3sXhslGhtLfE 24195548
    • Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection [plus supplementary appendix]. N Engl J Med. 2013;369(19):1807-18.
    • (2013) N Engl J Med. , vol.369 , Issue.19 , pp. 1807-1818
    • Walmsley, S.L.1    Antela, A.2    Clumeck, N.3
  • 20
    • 84904546476 scopus 로고    scopus 로고
    • Dolutegravir regimen statistically superior to tenofovir/emtricitabine/efavirenz: 96-wk data from the SINGLE study (ING114467) [abstract no. 543 plus poster]
    • Walmsley S, Berenguer J, Khuong-Josses MA. Dolutegravir regimen statistically superior to tenofovir/emtricitabine/efavirenz: 96-wk data from the SINGLE study (ING114467) [abstract no. 543 plus poster]. Top Antivir Med. 2014;22(e-1):261-2.
    • (2014) Top Antivir Med , vol.22 , Issue.e-1 , pp. 261-262
    • Walmsley, S.1    Berenguer, J.2    Khuong-Josses, M.A.3
  • 21
    • 84885948765 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
    • 1:CAS:528:DC%2BC3sXhsFeltLzJ 24074642
    • Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13(11):927-35.
    • (2013) Lancet Infect Dis. , vol.13 , Issue.11 , pp. 927-935
    • Raffi, F.1    Jaeger, H.2    Quiros-Roldan, E.3
  • 22
    • 84882912698 scopus 로고    scopus 로고
    • Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
    • 1:CAS:528:DC%2BC3sXhtVKrur7I 23830355
    • Cahn P, Pozniak AL, Mingrone H, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700-8.
    • (2013) Lancet. , vol.382 , Issue.9893 , pp. 700-708
    • Cahn, P.1    Pozniak, A.L.2    Mingrone, H.3
  • 23
    • 84903303497 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
    • 1:CAS:528:DC%2BC2cXltl2gt7k%3D 24698485
    • Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383(9936):2222-31.
    • (2014) Lancet. , vol.383 , Issue.9936 , pp. 2222-2231
    • Clotet, B.1    Feinberg, J.2    Van Lunzen, J.3
  • 24
    • 47949114939 scopus 로고    scopus 로고
    • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    • 1:CAS:528:DC%2BD1cXovFSqtb8%3D 18650513
    • Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008;359(4):355-65.
    • (2008) N Engl J Med. , vol.359 , Issue.4 , pp. 355-365
    • Cooper, D.A.1    Steigbigel, R.T.2    Gatell, J.M.3
  • 25
    • 84861136225 scopus 로고    scopus 로고
    • Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens
    • 3370736 1:CAS:528:DC%2BC38XnslWrsLY%3D 22450969
    • Garrido C, Villacian J, Zahonero N, et al. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother. 2012;56(6):2873-8.
    • (2012) Antimicrob Agents Chemother. , vol.56 , Issue.6 , pp. 2873-2878
    • Garrido, C.1    Villacian, J.2    Zahonero, N.3
  • 26
    • 80052847754 scopus 로고    scopus 로고
    • Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes
    • 3187001 1:CAS:528:DC%2BC3MXhtl2ns7fF 21807982
    • Hightower KE, Wang R, DeAnda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55(10):4552-9.
    • (2011) Antimicrob Agents Chemother. , vol.55 , Issue.10 , pp. 4552-4559
    • Hightower, K.E.1    Wang, R.2    DeAnda, F.3
  • 27
    • 80155188567 scopus 로고    scopus 로고
    • Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
    • 1:CAS:528:DC%2BC3MXhtlyqt7vN 21984737
    • Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204(11):1811-5.
    • (2011) J Infect Dis. , vol.204 , Issue.11 , pp. 1811-1815
    • Canducci, F.1    Ceresola, E.R.2    Boeri, E.3
  • 28
    • 84904721700 scopus 로고    scopus 로고
    • Impact of raltegravir/elvitegravir selected mutations on dolutegravir cross-resistance [abstract no. 595]
    • Huang W, Frantzell A, Whitcomb JM. Impact of raltegravir/elvitegravir selected mutations on dolutegravir cross-resistance [abstract no. 595]. Top Antivir Med. 2014;22(e-1):292-3.
    • (2014) Top Antivir Med , vol.22 , Issue.e-1 , pp. 292-293
    • Huang, W.1    Frantzell, A.2    Whitcomb, J.M.3
  • 29
    • 84929755856 scopus 로고    scopus 로고
    • Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients
    • Fourati S, Charpentier C, Amiel C, et al. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients. J Antimicrob Chemother. 2015. doi: 10.1093/jac/dku535.
    • (2015) J Antimicrob Chemother.
    • Fourati, S.1    Charpentier, C.2    Amiel, C.3
  • 30
    • 84898987717 scopus 로고    scopus 로고
    • Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
    • 4091579 1:CAS:528:DC%2BC2cXht1ygtrjL 24446523
    • Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210(3):354-62.
    • (2014) J Infect Dis. , vol.210 , Issue.3 , pp. 354-362
    • Castagna, A.1    Maggiolo, F.2    Penco, G.3
  • 31
    • 84904559099 scopus 로고    scopus 로고
    • New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors
    • 1:CAS:528:DC%2BC2cXht1SqsbfM 24710029
    • Malet I, Gimferrer Arriaga L, Artese A, et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother. 2014;69(8):2118-22.
    • (2014) J Antimicrob Chemother. , vol.69 , Issue.8 , pp. 2118-2122
    • Malet, I.1    Gimferrer Arriaga, L.2    Artese, A.3
  • 33
    • 84905735621 scopus 로고    scopus 로고
    • 2014 Update of the drug resistance mutations in HIV-1
    • 25101529
    • Wensing AM, Calvez V, Gunthard HF, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014;22(3):642-50.
    • (2014) Top Antivir Med. , vol.22 , Issue.3 , pp. 642-650
    • Wensing, A.M.1    Calvez, V.2    Gunthard, H.F.3
  • 34
    • 84862883245 scopus 로고    scopus 로고
    • Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization
    • 1:CAS:528:DC%2BC38XntVyms74%3D 22422361
    • Chen S, Min SS, Peppercorn A, et al. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization. Pharmacotherapy. 2012;32(4):333-9.
    • (2012) Pharmacotherapy. , vol.32 , Issue.4 , pp. 333-339
    • Chen, S.1    Min, S.S.2    Peppercorn, A.3
  • 35
    • 84874431501 scopus 로고    scopus 로고
    • A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects
    • 3612717 1:CAS:528:DC%2BC3sXktFOgtL8%3D 22905856
    • Koteff J, Borland J, Chen S, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990-6.
    • (2013) Br J Clin Pharmacol. , vol.75 , Issue.4 , pp. 990-996
    • Koteff, J.1    Borland, J.2    Chen, S.3
  • 36
    • 84861710765 scopus 로고    scopus 로고
    • Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
    • 1:CAS:528:DC%2BC38XhtFSqs7bL 22374987
    • Curran A, Martinez E, Podzamczer D, et al. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial. Antivir Ther. 2012;17(4):711-8.
    • (2012) Antivir Ther. , vol.17 , Issue.4 , pp. 711-718
    • Curran, A.1    Martinez, E.2    Podzamczer, D.3
  • 37
    • 84973228435 scopus 로고    scopus 로고
    • 48 week bone marker changes with dolutegravir (DTG) plus abacavir/lamivudine (ABC/3TC) vs. tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE trial [abstract no. P72]
    • Yazdanpanah Y, Khuong-Josses M, Hocqueloux L, et al. 48 week bone marker changes with dolutegravir (DTG) plus abacavir/lamivudine (ABC/3TC) vs. tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE trial [abstract no. P72]. BMC Infect Dis. 2014;14(Suppl 2):30.
    • (2014) BMC Infect Dis. , vol.14 , pp. 30
    • Yazdanpanah, Y.1    Khuong-Josses, M.2    Hocqueloux, L.3
  • 38
    • 84923689874 scopus 로고    scopus 로고
    • Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the Antiretroviral Pregnancy Registry
    • Vannappagari V, Koram N, Albano J, et al. Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the Antiretroviral Pregnancy Registry. J Acquir Immune Defic Syndr. 2014. doi: 10.1097/QAI.0000000000000465.
    • (2014) J Acquir Immune Defic Syndr
    • Vannappagari, V.1    Koram, N.2    Albano, J.3
  • 39
    • 84903776448 scopus 로고    scopus 로고
    • Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food
    • 1:CAS:528:DC%2BC2cXhtFSrtL7N 24798770
    • Weller S, Chen S, Borland J, et al. Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food. J Acquir Immune Defic Syndr. 2014;66(4):393-8.
    • (2014) J Acquir Immune Defic Syndr. , vol.66 , Issue.4 , pp. 393-398
    • Weller, S.1    Chen, S.2    Borland, J.3
  • 40
    • 84964314604 scopus 로고    scopus 로고
    • ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects
    • 4166983 24944232
    • Letendre SL, Mills AM, Tashima KT, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014;59(7):1032-7.
    • (2014) Clin Infect Dis. , vol.59 , Issue.7 , pp. 1032-1037
    • Letendre, S.L.1    Mills, A.M.2    Tashima, K.T.3
  • 41
    • 19544370354 scopus 로고    scopus 로고
    • Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid
    • 1140502 1:CAS:528:DC%2BD2MXkvFCgsbo%3D 15917556
    • Capparelli EV, Letendre SL, Ellis RJ, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother. 2005;49(6):2504-6.
    • (2005) Antimicrob Agents Chemother. , vol.49 , Issue.6 , pp. 2504-2506
    • Capparelli, E.V.1    Letendre, S.L.2    Ellis, R.J.3
  • 42
    • 84893485078 scopus 로고    scopus 로고
    • Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women
    • 4038682 1:CAS:528:DC%2BC2cXlvFymsr8%3D 23899439
    • Adams JL, Patterson KB, Prince HM, et al. Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women. Antivir Ther. 2013;18(8):1005-13.
    • (2013) Antivir Ther. , vol.18 , Issue.8 , pp. 1005-1013
    • Adams, J.L.1    Patterson, K.B.2    Prince, H.M.3
  • 43
    • 84883385762 scopus 로고    scopus 로고
    • Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing
    • 3804901 1:CAS:528:DC%2BC3sXht12jtL3L 23945251
    • Greener BN, Patterson KB, Prince HMA, et al. Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing. J Acquir Immune Defic Syndr. 2013;64(1):39-44.
    • (2013) J Acquir Immune Defic Syndr. , vol.64 , Issue.1 , pp. 39-44
    • Greener, B.N.1    Patterson, K.B.2    Prince, H.M.A.3
  • 44
    • 84880268976 scopus 로고    scopus 로고
    • Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans
    • 3719771 1:CAS:528:DC%2BC3sXht1Wgtb%2FO 23669385
    • Castellino S, Moss L, Wagner D, et al. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57(8):3536-46.
    • (2013) Antimicrob Agents Chemother. , vol.57 , Issue.8 , pp. 3536-3546
    • Castellino, S.1    Moss, L.2    Wagner, D.3
  • 45
    • 0029952016 scopus 로고    scopus 로고
    • Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction
    • 163359,1:CAS:528:DyaK28XjtlWmur8%3D 8726029
    • Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40(6):1514-9.
    • (1996) Antimicrob Agents Chemother. , vol.40 , Issue.6 , pp. 1514-1519
    • Heald, A.E.1    Hsyu, P.H.2    Yuen, G.J.3
  • 46
    • 84890448894 scopus 로고    scopus 로고
    • Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics
    • 1:CAS:528:DC%2BC3sXhvFensr3E 24329186
    • Chen S, St Jean P, Borland J, et al. Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics. Pharmacogenomics. 2014;15(1):9-16.
    • (2014) Pharmacogenomics. , vol.15 , Issue.1 , pp. 9-16
    • Chen, S.1    St Jean, P.2    Borland, J.3
  • 47
    • 84921304009 scopus 로고    scopus 로고
    • Dolutegravir (DTG) + abacavir/lamivudine once daily superior to tenofovir/emtricitabine/efavirenz in treatment naive HIV subjects: 144-week results from SINGLE (ING114467) [abstract no. H-647a]
    • Pappa K, Baumgarten A, Felizarta F, et al. Dolutegravir (DTG) + abacavir/lamivudine once daily superior to tenofovir/emtricitabine/efavirenz in treatment naive HIV subjects: 144-week results from SINGLE (ING114467) [abstract no. H-647a]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
    • (2014) 54th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Pappa, K.1    Baumgarten, A.2    Felizarta, F.3
  • 48
    • 84874411899 scopus 로고    scopus 로고
    • Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
    • 1:CAS:528:DC%2BC3sXnslyjtA%3D%3D 23306000
    • Raffi F, Rachlis A, Stellbrink H-J, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735-43.
    • (2013) Lancet. , vol.381 , Issue.9868 , pp. 735-743
    • Raffi, F.1    Rachlis, A.2    Stellbrink, H.-J.3
  • 49
    • 84929260080 scopus 로고    scopus 로고
    • Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO [abstract no. O153]
    • 4224885, 25393999
    • Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naive HIV-1-positive individuals: 96 week results from FLAMINGO [abstract no. O153]. J Int AIDS Soc. 2014;17(Suppl 3):19490.
    • (2014) J Int AIDS Soc. , vol.17 , pp. 19490
    • Molina, J.M.1    Clotet, B.2    Van Lunzen, J.3
  • 50
    • 84920262900 scopus 로고    scopus 로고
    • Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
    • 4284010 1:CAS:528:DC%2BC2cXitFKqsLvF 25387312
    • Raffi F, Rachlis A, Brinson C, et al. Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 2015;29(2):167-74.
    • (2015) AIDS. , vol.29 , Issue.2 , pp. 167-174
    • Raffi, F.1    Rachlis, A.2    Brinson, C.3
  • 52
    • 84939939065 scopus 로고    scopus 로고
    • An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine [abstract no. P247]
    • 4225386, 25397523
    • Rogatto F, Bouee S, Jeanbat V, et al. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine [abstract no. P247]. J Int AIDS Soc. 2014;17(Suppl 3):19779.
    • (2014) J Int AIDS Soc. , vol.17 , pp. 19779
    • Rogatto, F.1    Bouee, S.2    Jeanbat, V.3
  • 54
    • 84884554042 scopus 로고    scopus 로고
    • Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV
    • Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8). doi: 10.1136/bmjopen-2013-003028.
    • (2013) BMJ Open , vol.3 , Issue.8
    • Cohen, C.J.1    Meyers, J.L.2    Davis, K.L.3
  • 55
    • 84891110614 scopus 로고    scopus 로고
    • Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting
    • 3872009, 24379676
    • Colombo GL, Castagna A, Di Matteo S, et al. Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Ther Clin Risk Manag. 2014;10:9-15.
    • (2014) Ther Clin Risk Manag. , vol.10 , pp. 9-15
    • Colombo, G.L.1    Castagna, A.2    Di Matteo, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.